PCL Resp Dis Pt Resources v. 3

Food Insecurity and the Dangers of Infant Formula Dilution

Research in AJOG: Maternal hyperoxygenation doesn't boost neonatal Apgar scores in pathologic fetal heart rate tracing, showing no FiO2 benefit.

January 30th 2023

Incorporating objective testing to add value to an ADHD diagnosis

Perry Roy, MD | Image Credit: Carolina Attention Specialists

Demystifying Infant Formula

Perry Roy, MD, explains how an FDA-cleared objective test can assist in an ADHD diagnosis.

October 11th 2022

FDA approves tovorafenib for most common form of childhood brain tumor

April 24th 2024

First radioactive drug approved for patients 12 years and up with SSTR-positive GEP-NETs

This decision from the federal agency marks the first FDA approval of a systemic therapy to treat patients with pediatric LGG with BRAF rearrangements, including fusions.

April 23rd 2024

Study: Neonatal outcomes not associated with hyperoxygenation use

The FDA has approved lutetium Lu 177 dotatate for pediatric patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.

Related Content

Food Insecurity and the Dangers of Infant Formula Dilution

Research in AJOG: Maternal hyperoxygenation doesn't boost neonatal Apgar scores in pathologic fetal heart rate tracing, showing no FiO2 benefit.

January 30th 2023

Incorporating objective testing to add value to an ADHD diagnosis

Demystifying Infant Formula

Perry Roy, MD, explains how an FDA-cleared objective test can assist in an ADHD diagnosis.

October 11th 2022

FDA approves tovorafenib for most common form of childhood brain tumor

April 24th 2024

First radioactive drug approved for patients 12 years and up with SSTR-positive GEP-NETs

This decision from the federal agency marks the first FDA approval of a systemic therapy to treat patients with pediatric LGG with BRAF rearrangements, including fusions.

April 23rd 2024